Iron Chelator in Patients with Sickle Cell Anemia, Comparative Study
Kufa Journal for Nursing Sciences, 2014 Background: the two main reasons for blood transfusion in sickle cell disease are to correct anemia so that the oxygen-carrying capacity of the blood is improved, and to treat or prevent painful vasoocclusive by lowering the proportion of sickle cell ...
Talib Abduljaleel Jasim
doaj +1 more source
Effect of mercury vapor inhalation on rat ovary: stereology and histopathology [PDF]
, 2016 AimMercury, an environmental contaminant, is a risk factor for health in whole living organisms. In this study, we investigated whether mercury vapor (HgO) inhalation has an effect on rat ovary.
Akgul, Hayati Murat +6 more
core +1 more source
Toward optimizing the use of deferasirox: potential benefits of combined use with deferoxamine
Haematologica, 2013 Patients with β-thalassemia require iron chelation therapy to protect against progressive iron overload and non-transferrin-bound iron. Some patients fail to respond adequately to deferoxamine and deferasirox monotherapy while others have side effects ...
Robert W. Grady +5 more
doaj +1 more source
Case number 7 : Beta Thalassaemia Major with pulmonary hypertension [PDF]
, 2015 Mr. IB, a 29-year-old gentleman, who is a known case of beta thalassemia major, was referred from the emergency department following an episode of lethargy, cough, exertional dyspnoea and dyspepsia.
Gauci, Gabriel, Schembri, Christian
core
Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions [PDF]
, 2006 Ellis J. Neufeld
openalex +1 more source
Deferasirox desensitization [PDF]
The Journal of Allergy and Clinical Immunology: In Practice, 2016 Karen E, Bruner, Kevin M, White
openaire +2 more sources
PLoS ONE, 2018 Chronic blood transfusions are responsible to cause iron overload, which leads to several complications to end organs and osteoporosis. Iron chelation is needed to remove iron excess and to contain bone-mass loss. Deferasirox is the most recent oral iron
Francesca Punzo +5 more
doaj +1 more source
Deferiprone versus Deferoxamine in Sickle Cell Disease: Results from a 5-year long-term Italian multi-center randomized clinical trial. [PDF]
, 2014 Blood transfusion and iron chelation currently represent a supportive therapy to manage anemia, vasculopathy and vaso-occlusion crises in Sickle-Cell-Disease.
Ballas, Samir K. +10 more
core +2 more sources
A randomised comparison of deferasiroxversusdeferoxamine for the treatment of transfusional iron overload in sickle cell disease [PDF]
, 2006 Elliott Vichinsky +20 more
openalex +1 more source
Timing and characteristics of cumulative evidence available on novel therapeutic agents receiving Food and Drug Administration accelerated approval [PDF]
, 2017 Context: Therapeutic agents treating serious conditions are eligible for Food and Drug Administration (FDA) accelerated approval. The clinical evidence accrued on agents receiving accelerated approval has not been systematically evaluated.
Gupta, Radhika +3 more
core +1 more source